Imfinzi and Imjudo (durvalumab and tremelimumab)

Imjudo (tremelimumab for injection) in combination with durvalumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.